Etanercept biosimilar (Nanogen Biopharmaceutical)

依那西普生物类似药（Nanogen Biopharmaceutical）

Report date: 2022/01/14 13:23:58

Base Information

Drug NameEtanercept biosimilar (Nanogen Biopharmaceutical)
Drug Alias Name依那西普生物仿制药（Nanogen Biopharmaceutical）Nanercept
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion protein
Mechanisms of ActionTumor necrosis factor β inhibitorsTumor necrosis factor α inhibitors
TargetsTumor necrosis factor βTumor necrosis factor α
Therapy Area/IndicationsPsoriasisArthritis, Rheumatoid
Global Approved IndicationsPsoriasisArthritis, Rheumatoid
Approved Indications in ChinaN/A
Original Approved Country/TerritoryVietnam
Original Approved Date2019/01/01
Country/TerritoryVietnam
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesNanogen Biopharmaceutical Co
China Registration ClassN/A

Develop Information

Active CompaniesNanogen Biopharmaceutical Co
Inactive CompaniesN/A
Active IndicationsPsoriasisArthritis, Rheumatoid
Inactive IndicationsN/A

Other Information

ATC CodeL04AB01
Related LinksN/A